Home  >  Partners

At Tetra Bio-Pharma, partnering is integral to our business model and success. Our aim is to build strategic and productive partnerships that expand our innovative pharmaceutical pipeline. If you wish to obtain additional information about available opportunities or present us with a potential collaboration, we invite you to contact our business development group:

Bob Bechard
Executive Vice President, Corporate Development and Licensing

Please find a list of Tetra Bio-Pharma's development partners below:


Algorythm Pharma is conducting stage 1 clinical trials of PPP001 in collaboration with Tetra Bio-Pharma.


Aphria is a publicly traded producer of medical Cannabis under license from the Canadian Federal Government. Aphria has partnered with Tetra Bio-Pharma for the production of Cannabis for use in PPP001.


Tetra Bio-Pharma and IntelGenx Corp. have a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol XL - PPP002 for the management of anorexia and cancer chemotherapy-related pain.


McGill University is collaborating with Tetra Bio-Pharma on an NSERC (National Sciences and Engineering Research Council) funded research study to develop consumer products containing cannabinoids.


NSERC - The National Sciences and Engineering Research Council of Canada connects industry players with world-firsts in knowledge and the people behind them, fueling R&D and leading to firsts in the marketplace. They have granted Tetra Bio-Pharma with research funding related to the development of consumer products in collaboration with McGill University.


Tetra Bio-Pharma and Panag Pharma have a definitive agreement for two products, PPP003 and PPP004 for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion.


Tetra Bio-Pharma and The New Brunswick Health Research Foundation are investing a combined $1 million, $500,000 each over five years to establish a Health Research Chair in Cannabis at the University of New Brunswick (UNB). The chair will focus on the study of biochemistry, medicinal use and pharmacology of cannabis. This research will expand UNB’s commitment to research and innovation in the field of natural product and biomedical, health and life sciences – adding to its reputation as a leader in natural products’ research.